Alvograstim Indications/Uses

Alvograstim is indicated for: Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Mobilisation of peripheral blood progenitor cells (PBPCs).
Increase in neutrophil counts and reduction in the incidence and duration of infection-related events after long term administration in patients, children or adults, with severe congenital, cyclic or idiopathic neutropenia with an ANC of ≤0.5 x 10⁹/L, and a history of severe or recurrent infections.
Treatment of persistent neutropenia (ANC ≤1.0 x 10⁹/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.